1 / 17

STRATEGIC HEALTH PLAN AND ANTICIPATED CHANGES TO MRA/MCC Dr Joey Gouws Director: Inspectorate and Law Enforcement Medi

STRATEGIC HEALTH PLAN AND ANTICIPATED CHANGES TO MRA/MCC Dr Joey Gouws Director: Inspectorate and Law Enforcement Medicines Regulatory Authority (MRA) South Africa 04 September 2009. Index. Migration MCC/MRA to new Entity Operational MRA/MCC: EDMS Complementary Medicines

barth
Download Presentation

STRATEGIC HEALTH PLAN AND ANTICIPATED CHANGES TO MRA/MCC Dr Joey Gouws Director: Inspectorate and Law Enforcement Medi

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. STRATEGIC HEALTH PLAN AND ANTICIPATED CHANGES TO MRA/MCC Dr Joey Gouws Director: Inspectorate and Law Enforcement Medicines Regulatory Authority (MRA) South Africa 04 September 2009

  2. Index • Migration MCC/MRA to new Entity • Operational MRA/MCC: EDMS • Complementary Medicines • Marketing Code for Medicines • Regulations on API Manufacturing and Wholesaling

  3. MCC Mandate: Current • Registration of medicines • Control of Medical Devices • Authorisation and monitoring of Clinical trials • Monitoring of safety • Responses to signals • Licensing of Manufacturers and Wholesalers

  4. MCC/MRA Structure: Current • MCC and Expert Committees: External • MRA Cluster: Internal • Cluster Manager / Registrar • 4 Directorates

  5. MCC/MRA Structure: Future • Independent Public Entity ? • Parastatal Public Entity ?

  6. Reason for Restructuring • Reports from various Task Teams: • 1997, 1998, 2008, 2009 • Outcomes: • Under resourced • Under financed • Limited space • Infrastructure • Timelines to registration!!!

  7. New Structure: Requirements • Efficient MCC-priority for MoH • Envisage: amendment to the current legislation- HR, Finance, Processes • Registration timelines in legislation-internal evaluators v external evaluators • Contracts with performance indicators

  8. Interim measures: Backlog Task Team Appointed • Contracted 55 staff to work on backlog • Contracted 7 SAPC Inspectors to assist with GWP inspections

  9. To the South African Pharmaceutical Industry THANK YOU!

  10. Interim measures: Backlog Task Team Appointed….cont. • 3 Tier process: • 1st phase: Screening • 2nd phase: Audit • 3rd phase: Allocation to evaluators

  11. Interim measures: Backlog Task Team Appointed……cont. • Current status: • Screening up to date • Clinical trials up to date • Data base on applications • Space constraints: archive and move 7000 Metrofile boxes (30 October) • Licence applications / renewals • Weekly progress meetings

  12. Interim measures: Backlog Task Team Appointed……cont. • Special project (week 7 Sept): • Audit outcome available • MRA request info on 4 Committee resolutions • P&A Committee • Scheduling • Names • Clinical Committee

  13. Operational MRA/MCC: EDMS • MCC/MRA Server • EDMS • Specific process flow for each type of application (PI update, P&A Amendment) • Automatic eMail notification • No Screening • Training of MRA staff (6 week process): October 2009 • Implementation of eCTD: pilot run October 2009 • New MCC website: www.mra.gov.za

  14. Complementary medicines • MCC reviewed applications submitted • Serious concerns on the safety of the public • Urgent need for Regulatory control • Media release (2-3 weeks)

  15. Marketing Code for Medicines • Proposed Marketing Code: Industry • Final version: 24 August 2009 • Authority to enforce Code: Regulations • Regulatory compliance: add as “Condition of Registration”

  16. Regulations for control of API’s • Medicines Act mandate control: • Medicines • Related substances • Regulatory control of API’s • API: Manufacture and Wholesale licensing • API GMP-part of SA Guide (2007) • Constraint: Resources

  17. Enjoy your SAPRAA morning! Dr Joey Gouws Director: Inspectorate and Law Enforcement Medicines Regulatory Authority (MRA) South Africa email: gouwsj@health.gov.za

More Related